Key result
Donor NSAID use preserves platelet storage properties but aspirin and naproxen reduce arachidonic acid aggregation.
Why the study?
Buffy coats from donors who used NSAIDs are not used for platelet production due to concerns about inhibited platelet aggregation, necessitating investigation of in vitro platelet quality from these donors.
Are platelet concentrates prepared from donors who use NSAIDs functional when stored under standard blood bank conditions?
Are platelet concentrates prepared from donors who use NSAIDs functional when stored under standard blood bank conditions?
Platelet concentrates from donors using ibuprofen maintain normal aggregation and storage properties, suggesting they may be feasible for pooled buffy coat production.
Answers are grounded in this paper and cite their sources.
May support ibuprofen donor inclusion for platelet production; leaves open human efficacy validation.
Background and Objectives In our country, buffy coats (BCs) from donors who used non‐steroidal anti‐inflammatory drugs (NSAIDs) are not used for platelet (PLT) production, because NSAIDs inhibit platelet aggregation. We aimed to investigate the in vitro quality of PLT concentrates (PCs) prepared from NSAID BCs. Also a dose‐response study was performed with ibuprofen in PCs prepared from regular BCs. Materials and Methods Single‐donor PCs in plasma (sPCs, n = 18) were prepared from NSAID BCs. The type of NSAID was extracted from the donor questionnaire. Aliquots of pooled PC in PAS‐E (n = 3) were used to test dose‐response effects of ibuprofen. The PC (aliquots) was stored for 8 days at 22 ± 2°C and sampled regularly. Results Most NSAID donors used aspirin, diclofenac, ibuprofen or naproxen. Storage properties of PC were not measurably affected by NSAIDs. Aggregation tests with arachidonic acid revealed no differences with ibuprofen, which was in line with levels in donor plasma and the dose‐response study. A low or absent response was observed for sPC with aspirin (0, 0–60, median, range, P < 0·05), diclofenac (30, 0–93) and naproxen (0, 0–47, P < 0·05), compared to normal controls (69, 0–90). No differences were detected in aggregation with ADP or collagen. Conclusion No effects of NSAIDs on platelet storage properties were measured, but some effects on aggregation properties were present. The use of BC with ibuprofen can be considered feasible for pooled BC, due to pooling and dilution with PAS. For the other NSAIDs, except for aspirin which inhibits PLTs irreversibly, further study of NSAID BCs in pools is recommended.
No takes yet. Share an insight, caveat, or question.
Bontekoe et al. (2018) studied Blood donors using NSAIDs (n=21). NSAIDs (aspirin, diclofenac, ibuprofen, naproxen) vs. Normal controls (regular buffy coats) was evaluated on Platelet storage properties and aggregation response to arachidonic acid (p=<0.05). Platelet concentrates from donors using NSAIDs showed unaffected storage properties, but aggregation response to arachidonic acid was reduced for aspirin and naproxen compared to controls.
Synapse has enriched 10 related papers. Consider them for comparative context: